Danske Bank’s Impact BioMedical IBO Stock Holding History

Danske Bank’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1	Hold	3	–	–	﹤0.01%	1152
2026 Q1	$2	Hold	3	–	–	﹤0.01%	1151
2025 Q4	$2	Hold	3	–	–	﹤0.01%	1543
2025 Q3	$2	Hold	3	–	–	﹤0.01%	1475
2025 Q2	$2	Hold	3	–	–	﹤0.01%	1504
2025 Q1	$3	Hold	3	–	–	﹤0.01%	1338
2024 Q4	$4	Hold	3	–	–	﹤0.01%	1363
2024 Q3	$6	Buy	+3	New	+$7	﹤0.01%	1551

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Danske Bank's IBO Position: Q2 2026 in Review

Danske Bank held its Impact BioMedical (IBO) position steady in Q2 2026 at 3 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

Danske Bank first reported a position in IBO in Q3 2024 and has held it in 8 quarters since. The position peaked at $6 in Q3 2024. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

Danske Bank held 3 shares of Impact BioMedical worth $1 as of Q2 2026.
Danske Bank left its Impact BioMedical share count unchanged in Q2 2026.
Impact BioMedical made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1152 holding.
Danske Bank first reported a position in Impact BioMedical in Q3 2024 and has held it in 8 quarters since.
Danske Bank's Impact BioMedical position peaked at $6 in Q3 2024.
22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.